PE 22-28

How It Works:
PE-22-28, a groundbreaking peptide with promising potential in the treatment of major depressive disorder, mood regulation, and
cognitive enhancement. This synthetic derivative of the naturally occurring protein Spadin offers a new approach to mental health
management. PE-22-28 specifically blocks the TREK-1 (TWIK-related potassium channel) receptor, a two-pore potassium channel
identified as a crucial target for treating depression. Brain Function Regulation: This peptide plays a significant role in regulating the
TREK-1 pathway in the central nervous system, particularly in areas like the prefrontal cortex and hippocampus, which are key for mood,
memory, and learning. Rapid Neurogenesis: Remarkably, PE-22-28 induces neurogenesis in just four days, far quicker than traditional
therapies, thereby accelerating the recovery process in depression treatments. Effective Antidepressant Properties: In vivo studies have
demonstrated its potential as an antidepressant. Mice treated with PE-22-28 showed reduced signs of depression and enhanced
cognitive abilities.
Key Benefits:
Depression Management: PE-22-28 helps manage symptoms of depression, including post-stroke depression (PSD). Cognitive
Health: The peptide stimulates synaptogenesis and upregulates neurogenesis, contributing to improved cognitive health.
Muscle and Neurological Health: It aids in muscle function and is beneficial for individuals with neurodegenerative diseases.
Content & Potency:
Injectable
10mg Vial: Reconstitute 5ml with BWFI (2mg/ml – 5ml) Inject 0.10 – 0.20ml subcutaneously 5 days a week